Cargando…

Real world safety of CT-P10 (anti-CD 20 monoclonal antibodies biosimilar) in rheumatic and autoimmune diseases

BACKGROUND: Rituximab (RTX), anti-CD 20 monoclonal antibodies, has been approved for many rheumatic and autoimmune diseases, the use of RTX is still limited due to financial constrain. Biosimilar RTX may increase access by offering patients a more affordable option, lead to improved patient outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katchamart, Wanruchada, Ngamjanyaporn, Pintip, Orawongpaisarn, Annop, Phubangkertphon, Thossapoom, Borrirukwisitsak, Sasimon, Dechapaphapitak, Nichapa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710159/ https://www.ncbi.nlm.nih.gov/pubmed/36447248 http://dx.doi.org/10.1186/s41927-022-00306-7

Ejemplares similares

Efficacy and safety of rituximab biosimilar in refractory lupus
por: Pongtarakulpanit, Nantakarn, et al.
Publicado: (2020)

Assessment of transition readiness in adolescents in Thailand with rheumatic diseases: a cross-sectional study
por: Kittivisuit, Sirinthip, et al.
Publicado: (2021)

Risk Factors, Clinical Characteristics, Management, and Outcomes of Musculoskeletal Fungal Infection at Thailand’s Largest National Tertiary Referral Center
por: Chokevittaya, Piyaporn, et al.
Publicado: (2022)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Health-related quality of life in patients with rheumatoid arthritis
por: Katchamart, Wanruchada, et al.
Publicado: (2019)

Validity and Reliability of the Thai Version of the 19-Item Compliance-Questionnaire-Rheumatology
por: Panichaporn, Saranya, et al.
Publicado: (2022)

Clinical Characteristics of Anti-Synthetase Syndrome and Variables Associated with Interstitial Lung Disease and Mortality: A Retrospective Cohort Study
por: Sodsri, Tulaton, et al.
Publicado: (2023)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

Therapeutic Monoclonal Antibodies and Emergence of Their Biosimilars
por: Jeddi-Tehrani, Mahmood
Publicado: (2018)

Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies
por: Doevendans, Erik, et al.
Publicado: (2019)

Factors for starting biosimilar TNF inhibitors in patients with rheumatic diseases in the real world
por: Sung, Yoon-Kyoung, et al.
Publicado: (2020)

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry
por: Nabi, Hafsah, et al.
Publicado: (2022)

Cutaneous and Extracutaneous Manifestations of Behçet’s Disease Linked to Its Disease Activity and Prognosis
por: Limtong, Preeyachat, et al.
Publicado: (2020)

Trichoscopic Signs in Dermatomyositis, Systemic Lupus Erythematosus, and Systemic Sclerosis: A Comparative Study of 150 Patients
por: Chanprapaph, Kumutnart, et al.
Publicado: (2022)

2222. A study of the role of trimethoprim-sulfamethoxazole in opportunistic infection prevention in lupus patients taking low-level immunosuppressive treatment: An open-labeled, randomized controlled trial
por: Munthananuchat, Paopat, et al.
Publicado: (2023)

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
por: Moorkens, Evelien, et al.
Publicado: (2016)

Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study
por: Vergara-Dangond, Cristina, et al.
Publicado: (2017)

Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases
por: Kiltz, Uta, et al.
Publicado: (2022)

Prospective Pilot Study of Cyclophosphamide as an Adjunct Treatment in Patients With Adult-Onset Immunodeficiency Associated With Anti-interferon-γ Autoantibodies
por: Laisuan, Wannada, et al.
Publicado: (2020)

Expert perspectives on biosimilar monoclonal antibodies in breast cancer
por: Cortés, J., et al.
Publicado: (2014)

Biosimilar monoclonal antibodies in China: A patent review
por: Liu, Jia-Wei, et al.
Publicado: (2022)

Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases
por: Schulze-Koops, Hendrik
Publicado: (2017)

Perceptions towards biologic and biosimilar therapy of patients with rheumatic and gastroenterological conditions
por: Khoo, Thomas, et al.
Publicado: (2022)

Serum sickness-like reaction following an administration of the first dose of inactivated COVID19 vaccine
por: Chaijaras, Sasipim, et al.
Publicado: (2021)

Editorial: Biological drugs and biosimilars in autoimmune diseases
por: Wajda, Anna, et al.
Publicado: (2023)

Autoimmune Rheumatic Diseases
por: Anaya, Juan-Manuel, et al.
Publicado: (2014)

EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies
por: Francescon, Sara, et al.
Publicado: (2018)

The model of circulating immune complexes and interleukin-6 improves the prediction of disease activity in systemic lupus erythematosus
por: Thanadetsuntorn, Chokchai, et al.
Publicado: (2018)

2684. The Prospective Pilot Study of Infectious Complication Surveillance in Active Systemic Lupus Erythematosus Patients with Intense Immunosuppressive Therapy: Cellular Response and Clinical Outcomes
por: Rotjanapan, Porpon, et al.
Publicado: (2019)

2655. A Prospective Study of Cytomegalovirus Infection in Active Systemic Lupus Erythematosus Patients with Intense Immunosuppressive Therapy: Epidemiology, Associated Risk Factors, Pathogenesis, and Clinical Outcomes
por: Bushyakanist, Asalaysa, et al.
Publicado: (2019)

Interchangeability and adverse events in originator-rituximab and its biosimilar (CT-P10) among rheumatic patients: a real-life experience
por: Bahap-Kara, Melda, et al.
Publicado: (2023)

Real-life effectiveness of budesonide/formoterol maintenance and reliever therapy in asthma patients across Asia: SMARTASIA study
por: Zhong, Nanshan, et al.
Publicado: (2013)

Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
por: Du, Fanny Huynh, et al.
Publicado: (2017)

Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin
por: Ly, Sophia, et al.
Publicado: (2023)

Curcumin in Autoimmune and Rheumatic Diseases
por: Yang, Melissa, et al.
Publicado: (2019)

Regulatory challenges with biosimilars: an update from 20 countries
por: Kang, Hye‐Na, et al.
Publicado: (2020)

1147. A study of high-dose influenza vaccination responses compared to standard-dose in lupus patients: an open- labeled, randomized controlled study
por: Yingyounyong, Sasicha, et al.
Publicado: (2023)

Autoimmune polyendocrine syndromes associated with autoimmune rheumatic diseases
por: Jankowska, Katarzyna, et al.
Publicado: (2023)

Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges
por: Chapman, Kathryn, et al.
Publicado: (2016)

Biosimilar structural comparability assessment by NMR: from small proteins to monoclonal antibodies
por: Japelj, Boštjan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mnbphhaps5hjec2n76cu06p1g6